Abstract
Trialing has long been recommended, and may even be required by health insurance payers, to determine whether a patient is an appropriate candidate for an implantable intrathecal infusion system. Despite work specific to trialing in the nonmalignant pain patient population[1] there is a paucity of evidence demonstrating the predictive value of a trial or a significant association between the type of trialing technique and the long-term effectiveness of an implanted system[2],[3],[4],[5]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
